•
KL
KLTOW
Klotho Neurosciences, Inc. Warrant
polygonBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
--
Volume
739.00
52W High
$0.95
52W Low
$0.01
Open
$0.11
Prev Close
$0.11
Day Range
0.11 - 0.11
About Klotho Neurosciences, Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
Latest News
Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets
Benzinga•Jul 22
Klotho Clears Nasdaq Hurdle—KLTO Stock Remains On The Big Board
Benzinga•Jul 16
Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco
GlobeNewswire Inc.•Jan 8
Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences’ Scientific Advisory Board
GlobeNewswire Inc.•Dec 9
Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences
GlobeNewswire Inc.•Oct 15
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
GlobeNewswire Inc.•Sep 30
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
GlobeNewswire Inc.•Sep 30